Marker Therapeutics, Inc. — Director's Dealing 2017

Mar 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC (TPIV)
CIK: 0001094038
Period of Report: 2017-03-09

Reporting Person: BONFIGLIO JOHN N (Director, President and COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-03-09	Common Stock	A	5220	—	Acquired	26054	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	10417	Indirect

Footnotes

F1: Represents the portion of a discretionary bonus award for 2016 payable as a restricted, immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan. The issuance of 5,220 shares of restricted common stock was based on the closing price or our common stock of $4.31 per share, on the day immediately preceding the date the 2016 bonus award was approved.